Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warning
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
In the last 2 years, regulatory agencies in the UK and the USA have made recommendations and “black box” warnings, regarding the use of atypical antipsychotic drugs in the elderly because of a purported increase in risk of stroke and death in elderly demented patients. These advisories did not address the adverse effects of “typical” (first-generation) antipsychotics. In this article, the author reviews the history of these developments and raises issues that still need to be addressed by the neurologic community.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning
- Carl E. Rosenkilde, MD, PhD, Northern Westchester Hospital, 91 Smith Avenue, Mount Kisco, NY 10549maribo@aol.com
Submitted October 25, 2006 - Reply from the Author
- Joseph H Friedman, NeuroHealth, 227 Centerville Rd , Warwick, RI 02886Joseph_Friedman@brown.edu
- Warwick, RI 02886
Submitted October 25, 2006
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Deborah Friedman and Dr. Stacy Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Review
PimavanserinA novel therapeutic option for Parkinson disease psychosisTrevor Hawkins, Brian D. Berman et al.Neurology: Clinical Practice, March 24, 2017 -
Editorial
PimavanserinA Friend or Foe in Parkinson Disease PsychosisFarwa Ali et al.Neurology, August 13, 2021 -
Clinical/Scientific Notes
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapineGabriel M. Moreno, Rhea Gandhi, Stephanie L. Lessig et al.Neurology, September 26, 2018 -
Special Article
Evidence-based guideline: Treatment of tardive syndromesReport of the Guideline Development Subcommittee of the American Academy of NeurologyRoongroj Bhidayasiri, Stanley Fahn, William J. Weiner et al.Neurology, July 29, 2013